Journal of Diabetes Investigation最新文献

{"title":"Association between early-stage diabetic nephropathy and the delayed monophasic glucose peak during oral glucose tolerance test in type 2 diabetes mellitus","authors":"Han Zhang,&nbsp;Hanqing Tang,&nbsp;Yunjuan Gu,&nbsp;Zhuqi Tang,&nbsp;Xiaoqin Zhao,&nbsp;Ranran Zhou,&nbsp;Ping Huang,&nbsp;Rongping Zhang,&nbsp;Xinlei Wang","doi":"10.1111/jdi.14382","DOIUrl":"10.1111/jdi.14382","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To explore the relationships between the delayed monophasic glucose peak during oral glucose tolerance test (OGTT) and early-stage diabetic nephropathy (DN) in patients with type 2 diabetes mellitus(T2DM), and to speculate its potential as a risk factor for early-stage DN.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This retrospective observational study included 448 participants, all of whom underwent a 3-h OGTT. Based on peak glucose time, they were categorized into the normal glucose tolerance (NGT) group (<i>n</i> = 76), the early delayed group (<i>n</i> = 98), and the late delayed group (<i>n</i> = 274) for comparison. Furthermore, T2DM patients were subdivided into the non-DN group (<i>n</i> = 293) and the early-stage DN group (<i>n</i> = 79) for comparative analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>With the delay in glucose peak time, blood glucose levels increased, insulin secretion function and insulin sensitivity decreased. In logistic regression, ISSI-2 was independently associated with the delay in glucose peak time in patients with T2DM (OR 0.839; 95% CI 0.776–0.907; <i>P</i> &lt; 0.001). Additionally, 2-h plasma glucose, OGIS, and AUC_{C-peptide0–180 min} were independently associated with delayed peak glucose time (all <i>P</i> &lt; 0.001). As glucose peak time was delayed, levels of β2-microglobulin and UACR increased, and the prevalence of early-stage DN also increased (all <i>P</i> &lt; 0.050). The delayed monophasic glucose peak was positively associated with early-stage DN (OR 2.230; 95% CI 1.061–4.687; <i>P</i> = 0.034).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with T2DM, the delayed monophasic glucose peak during OGTT may be an early predictor of early-stage diabetes nephropathy, providing early intervention signals for our clinical work.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"236-245"},"PeriodicalIF":3.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume 15","authors":"","doi":"10.1111/jdi.14374","DOIUrl":"https://doi.org/10.1111/jdi.14374","url":null,"abstract":"&lt;p&gt;50-g Oral glucose challenge test&lt;/p&gt;&lt;p&gt;Problems in screening for gestational diabetes mellitus by measurement of casual blood glucose levels at 24–28 gestational weeks, Tomimoto 1797–1802.&lt;/p&gt;&lt;p&gt;β-Cell dysfunction&lt;/p&gt;&lt;p&gt;Glucose metabolism partially regulates β-cell function through epigenomic changes, Kim 649–655.&lt;/p&gt;&lt;p&gt;β-Cells&lt;/p&gt;&lt;p&gt;Role of β-cell autophagy in β-cell physiology and the development of diabetes, Yasasilka 656–668.&lt;/p&gt;&lt;p&gt;β-Cell mass&lt;/p&gt;&lt;p&gt;Effects of glucokinase haploinsufficiency on the pancreatic β-cell mass and function of long-term high-fat, high-sucrose diet-fed mice, Shigesawa 1732–1742.&lt;/p&gt;&lt;p&gt;Accuracy&lt;/p&gt;&lt;p&gt;Impact of hematocrit levels on the accuracy of specific blood glucose meters: A hospital-based study, Pham 1472–1482.&lt;/p&gt;&lt;p&gt;Acyl-coenzyme A synthetase long-chain family member 4&lt;/p&gt;&lt;p&gt;Tanshinone IIA suppresses ferroptosis to attenuate renal podocyte injury in diabetic nephropathy through the embryonic lethal abnormal visual-like protein 1 and acyl-coenzyme A synthetase long-chain family member 4 signaling pathway, Zhu 1003–1016.&lt;/p&gt;&lt;p&gt;Adherence&lt;/p&gt;&lt;p&gt;Modification effect of receipt of diabetes care on the association between COVID-19 infection and HbA1c level during the first year of the coronavirus pandemic using a nationwide population-based database, Okada 953–963.&lt;/p&gt;&lt;p&gt;Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: A systematic review and meta-analysis, Boonpattharatthiti 1614–1625.&lt;/p&gt;&lt;p&gt;Aging&lt;/p&gt;&lt;p&gt;Association of biomarkers and Barthel Index with occurrence of age-related adverse health outcomes in individuals with diabetes, Umamoto 1675–1683.&lt;/p&gt;&lt;p&gt;Alcohol drinking&lt;/p&gt;&lt;p&gt;The association between alcohol drinking and glycemic management among people with type 2 diabetes in China, Ye 237–244.&lt;/p&gt;&lt;p&gt;Aldehyde dehydrogenase 2&lt;/p&gt;&lt;p&gt;Mitochondrial ALDH2 improves β-cell survival and function against doxorubicin-induced apoptosis by targeting CK2 signaling, Karunakaran 684–692.&lt;/p&gt;&lt;p&gt;Algorithm&lt;/p&gt;&lt;p&gt;A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd edition (English version), Bouchi 1326–1342.&lt;/p&gt;&lt;p&gt;Alzheimer's disease-like complications of DM&lt;/p&gt;&lt;p&gt;Calpeptin improves the cognitive function in Alzheimer's disease-like complications of diabetes mellitus rats by regulating TXNIP/NLRP3 inflammasome, Qiao 1365–1376.&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4 is a potential biomarker for diabetic kidney disease in type 2 diabetes patients, Wang 1763–1772.&lt;/p&gt;&lt;p&gt;Antidiabetic drugs&lt;/p&gt;&lt;p&gt;Cancer biology in diabetes update: Focusing on antidiabetic drugs, Kawakita 525–540.&lt;/p&gt;&lt;p&gt;Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes, Moon 669–683.&lt;/p&gt;&lt;p&gt;Anti-inflammatory activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabetes: Structural and functional relevance, Lui 805–816.&lt;/p&gt;&lt;p&gt;Anti-oxidative activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabete","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1841-1861"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"10.1111/jdi.14324","DOIUrl":"https://doi.org/10.1111/jdi.14324","url":null,"abstract":"&lt;p&gt;The publication of invaluable papers in the Journal of Diabetes Investigation depends on the prompt, careful review of submitted manuscripts. We would like to thank the Editorial Board members, the International Editorial Board members, the Assistant Editorial Board members and the following experts for reviewing manuscripts from September 1, 2023 to August 31, 2024.&lt;/p&gt;&lt;p&gt;Mohammed S. Abusamaan&lt;/p&gt;&lt;p&gt;Adegbenga B. Ademolu&lt;/p&gt;&lt;p&gt;Houssein Ahmadi&lt;/p&gt;&lt;p&gt;Zubair Ahmed&lt;/p&gt;&lt;p&gt;Ken-Ichi Aihara&lt;/p&gt;&lt;p&gt;Yoichi Ajiro&lt;/p&gt;&lt;p&gt;Satoru Akazawa&lt;/p&gt;&lt;p&gt;Hamed Akbari&lt;/p&gt;&lt;p&gt;Gulali Aktas&lt;/p&gt;&lt;p&gt;Nurshad Ali&lt;/p&gt;&lt;p&gt;Shigeru Aoki&lt;/p&gt;&lt;p&gt;Tomohisa Aoyama&lt;/p&gt;&lt;p&gt;Keiko Arai&lt;/p&gt;&lt;p&gt;Atsushi Araki&lt;/p&gt;&lt;p&gt;Osamu Arisaka&lt;/p&gt;&lt;p&gt;Shunichiro Asahara&lt;/p&gt;&lt;p&gt;Kenji Ashida&lt;/p&gt;&lt;p&gt;Yoshimasa Aso&lt;/p&gt;&lt;p&gt;Hande Atalay&lt;/p&gt;&lt;p&gt;Ahmad Khusairi Azemi&lt;/p&gt;&lt;p&gt;Kengo Azushima&lt;/p&gt;&lt;p&gt;Masayuki Baba&lt;/p&gt;&lt;p&gt;Asaad Ma Babker&lt;/p&gt;&lt;p&gt;Mohamed F. Balaha&lt;/p&gt;&lt;p&gt;Ryotaro Bouchi&lt;/p&gt;&lt;p&gt;David S. Boyer&lt;/p&gt;&lt;p&gt;Ali Cetin&lt;/p&gt;&lt;p&gt;Chi-Ming Chan&lt;/p&gt;&lt;p&gt;Te-Fu Chan&lt;/p&gt;&lt;p&gt;Min-Cheol Chang&lt;/p&gt;&lt;p&gt;Deqing Chen&lt;/p&gt;&lt;p&gt;Deyan Chen&lt;/p&gt;&lt;p&gt;Harn-Shen Chen&lt;/p&gt;&lt;p&gt;Juncao Chen&lt;/p&gt;&lt;p&gt;Ming-Wei Chen&lt;/p&gt;&lt;p&gt;Yang Ching Chen&lt;/p&gt;&lt;p&gt;Yen-Lin Chen&lt;/p&gt;&lt;p&gt;Yi-Rong Chen&lt;/p&gt;&lt;p&gt;Kenneth Cheng&lt;/p&gt;&lt;p&gt;Kyu Yong Cho&lt;/p&gt;&lt;p&gt;Soo Choi&lt;/p&gt;&lt;p&gt;Chih-Hsun Chu&lt;/p&gt;&lt;p&gt;Daisuke Chujo&lt;/p&gt;&lt;p&gt;Seung Min Chung&lt;/p&gt;&lt;p&gt;Dana Mihaela Ciobanu&lt;/p&gt;&lt;p&gt;Flávia Campos Corgosinho&lt;/p&gt;&lt;p&gt;Andre Luiz Costa&lt;/p&gt;&lt;p&gt;Xiaona Cui&lt;/p&gt;&lt;p&gt;Makoto Daimon&lt;/p&gt;&lt;p&gt;Taura Daisuke&lt;/p&gt;&lt;p&gt;Undurti Das&lt;/p&gt;&lt;p&gt;Takahisa Deguchi&lt;/p&gt;&lt;p&gt;Masashi Demura&lt;/p&gt;&lt;p&gt;Wuquan Deng&lt;/p&gt;&lt;p&gt;Sunil Deshpande&lt;/p&gt;&lt;p&gt;Domenico Di Raimondo&lt;/p&gt;&lt;p&gt;Yu Ding&lt;/p&gt;&lt;p&gt;Kentaro Doi&lt;/p&gt;&lt;p&gt;Jocelyn J. Drinkwater&lt;/p&gt;&lt;p&gt;Joao M. N. Duarte&lt;/p&gt;&lt;p&gt;Tuba Duman&lt;/p&gt;&lt;p&gt;Jun Eguchi&lt;/p&gt;&lt;p&gt;Akira Endo&lt;/p&gt;&lt;p&gt;Kang-Chih Fan&lt;/p&gt;&lt;p&gt;Lei Feng&lt;/p&gt;&lt;p&gt;Gabor Ferneisz&lt;/p&gt;&lt;p&gt;Chia-Po Fu&lt;/p&gt;&lt;p&gt;Toshihito Fujii&lt;/p&gt;&lt;p&gt;Rumi Fujikawa&lt;/p&gt;&lt;p&gt;Junji Fujikura&lt;/p&gt;&lt;p&gt;Shimpei Fujimoto&lt;/p&gt;&lt;p&gt;Shiho Fujisaka&lt;/p&gt;&lt;p&gt;Yoshihito Fujita&lt;/p&gt;&lt;p&gt;Yukihiro Fujita&lt;/p&gt;&lt;p&gt;Yoshio Fujitani&lt;/p&gt;&lt;p&gt;Michiaki Fukui&lt;/p&gt;&lt;p&gt;Masato Furuhashi&lt;/p&gt;&lt;p&gt;Shinya Furukawa&lt;/p&gt;&lt;p&gt;Hiroto Furuta&lt;/p&gt;&lt;p&gt;Yechiel N. Gellman&lt;/p&gt;&lt;p&gt;Stacey Gorniak&lt;/p&gt;&lt;p&gt;Atsushi Goto&lt;/p&gt;&lt;p&gt;Weaam Gouda&lt;/p&gt;&lt;p&gt;Alpesh Goyal&lt;/p&gt;&lt;p&gt;Tanja Groten&lt;/p&gt;&lt;p&gt;Xuejiang Gu&lt;/p&gt;&lt;p&gt;Yunjuan Gu&lt;/p&gt;&lt;p&gt;Keyu Guo&lt;/p&gt;&lt;p&gt;Kyoung Hwa Ha&lt;/p&gt;&lt;p&gt;Masahide Hamaguchi&lt;/p&gt;&lt;p&gt;Akihiro Hamasaki&lt;/p&gt;&lt;p&gt;Toshiaki Hanafusa&lt;/p&gt;&lt;p&gt;Rikinari Hanayama&lt;/p&gt;&lt;p&gt;Shinichi Harashima&lt;/p&gt;&lt;p&gt;Goji Hasegawa&lt;/p&gt;&lt;p&gt;Koshi Hashimoto&lt;/p&gt;&lt;p&gt;Yoshitaka Hashimoto&lt;/p&gt;&lt;p&gt;Nabil A. Hasona&lt;/p&gt;&lt;p&gt;Yuji Hataya&lt;/p&gt;&lt;p&gt;Yoshitaka Hayashi&lt;/p&gt;&lt;p&gt;Yasuaki Hayashino&lt;/p&gt;&lt;p&gt;Sakoda Hideyuki&lt;/p&gt;&lt;p&gt;Shinji Higuchi&lt;/p&gt;&lt;p&gt;Tatsuhito Himeno&lt;/p&gt;&lt;p&gt;Tsutomu Hirano&lt;/p&gt;&lt;p&gt;Satoshi Hirayama&lt;/p&gt;&lt;p&gt;Takahisa Hirose&lt;/p&gt;&lt;p&gt;Inoue Hiroshi&lt;/p&gt;&lt;p&gt;Yushi Hirota&lt;/p&gt;&lt;p&gt;Takanori Honda&lt;/p&gt;&lt;p&gt;Minha Hong&lt;/p&gt;&lt;p&gt;Ruby Hoo&lt;/p&gt;&lt;p&gt;Ichiro Horie&lt;/p&gt;&lt;p&gt;Takeshi Horii&lt;/p&gt;&lt;p&gt;Yukio Horikawa&lt;/p&gt;&lt;p&gt;Masayuki Hosoi&lt;/p&gt;&lt;p&gt;Yi-Ting Hsieh&lt;/p&gt;&lt;p&gt;Paul Hsu&lt;/p&gt;&lt;p&gt;Cheng Hu&lt;/p&gt;&lt;p&gt;Haofei Hu&lt;/p&gt;&lt;p&gt;Chia-Luen Huang&lt;/p&gt;&lt;p&gt;Chuiguo Huang&lt;/p&gt;&lt;p&gt;Cn Huang&lt;/p&gt;&lt;p&gt;Yu-Tung Huang&lt;/p&gt;&lt;p&gt;Zhimin Huang&lt;/p&gt;&lt;p&gt;Mikael S Huhtala&lt;/p&gt;&lt;p&gt;Sartaj Hussain&lt;/p&gt;&lt;p&gt;You-Cheol H","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1838-1840"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Non-classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease”","authors":"Mostafa Javanian,&nbsp;Mohammad Barary,&nbsp;Soheil Bakhshinasab,&nbsp;Soheil Ebrahimpour","doi":"10.1111/jdi.14356","DOIUrl":"10.1111/jdi.14356","url":null,"abstract":"&lt;p&gt;We read with great interest the article titled “Non-classical Monocyte Frequency and Serum Vitamin D3 Levels are Linked to Diabetic Foot Ulcer Associated with Peripheral Artery Disease,” published in your esteemed journal&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. The research highlights the reduced frequency of non-classical monocytes and low vitamin D3 levels in patients with diabetic foot ulcers (DFUs) associated with peripheral artery disease (PAD), shedding light on the potential role of these factors in DFU pathogenesis. We commend the authors for this valuable contribution, but we believe several methodological improvements could further enhance the study's impact.&lt;/p&gt;&lt;p&gt;The study's focus on limited laboratory markers may have overlooked other potential indicators. Additional biomarkers, such as calcium, potassium, uric acid, liver function tests, and indices like the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI), could provide deeper insights into the inflammatory processes at play in DFU patients&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;. This might help better predict poor outcomes.&lt;/p&gt;&lt;p&gt;Although the Meggitt–Wagner classification provided useful data, it lacks a clear focus on vascular involvement. Other classification systems, such as the PEDIS and SINBAD systems, which evaluate factors like perfusion, depth, infection, and ischemia, could offer a more comprehensive assessment of DFUs and their correlation with PAD&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;The study did not explore other medications beyond antidiabetic drugs that patients might have been using, nor did it address the impact of conditions like cancer, hematologic disorders, or autoimmune diseases. These factors can influence immune function and thus alter the study outcomes.&lt;/p&gt;&lt;p&gt;Alcohol consumption was not investigated, despite its known role in DFU outcomes. Additionally, categorizing smoking status into non-smokers, former smokers, and current smokers could provide a clearer picture of its impact on DFU development and progression.&lt;/p&gt;&lt;p&gt;Classifying PAD into mild, moderate, and severe categories and comparing the frequency of non-classical monocytes and vitamin D3 levels across these groups would enrich the analysis, offering more nuanced insights into the relationship between PAD severity and immune response.&lt;/p&gt;&lt;p&gt;The relatively small sample size of the study could limit its statistical power, leading to wider margins of error. A larger cohort would increase the robustness of the findings, ensuring better generalizability and precision&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;In conclusion, while this study makes a significant contribution to our understanding of the relationship between non-classical monocytes, vitamin D3, and DFUs associated with PAD, addressing the outlined limitations would strengthen the findings and their implications. We believe that future studies incorporating these factors could further advance research in this critical area.&lt;/p&gt;&lt;p&gt;The aut","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"350-351"},"PeriodicalIF":3.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in prescribing sodium-glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular-renal disease in South Korea, 2015–2021","authors":"Kyoung Hwa Ha,&nbsp;Soyoung Shin,&nbsp;EunJi Na,&nbsp;Dae Jung Kim","doi":"10.1111/jdi.14363","DOIUrl":"10.1111/jdi.14363","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study evaluates shifts in oral glucose-lowering drug prescription patterns and the adoption of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in South Korea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional and retrospective cohort analysis of the Korean National Health Insurance database (2015–2021) assessed the prescription patterns of oral glucose-lowering drugs by therapy level, SGLT2i prescriptions by cardiovascular-renal disease (CVRD) status, and the mean duration for SGLT2i therapy initiation and intensification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 2015 to 2021, the number of individuals prescribed oral glucose-lowering drugs across all regimen levels increased. However, the proportion of individuals receiving monotherapy or dual combination therapy decreased by 9.2 percentage points, whereas the proportion prescribed triple or more combination therapy increased. SGLT2i prescriptions increased from 2.5% in 2015 to 13.9% in 2021, marking an 11.4 percentage point growth. This trend was consistent among individuals with and without CVRD, with the most significant increase observed in individuals with heart failure—from 2.2% in 2015 to 16.6%. The mean time to SGLT2i initiation post-diagnosis was shortened from 249 days in 2015 to 158 days in 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The adoption of SGLT2i therapy was on the rise, especially among individuals with heart failure, accompanied by a notable decrease in time to treatment initiation. Despite these positive trends, the overall use of SGLT2i among individuals with CVRD remained limited.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"215-224"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes","authors":"Koichi Asahi,&nbsp;Tsuneo Konta,&nbsp;Kouichi Tamura,&nbsp;Fumitaka Tanaka,&nbsp;Akira Fukui,&nbsp;Yusuke Nakamura,&nbsp;Junichi Hirose,&nbsp;Kenichi Ohara,&nbsp;Yoko Shijoh,&nbsp;Matthew Carter,&nbsp;Kimberley Meredith,&nbsp;James Harris,&nbsp;Örjan Åkerborg,&nbsp;Naoki Kashihara,&nbsp;Takashi Yokoo","doi":"10.1111/jdi.14293","DOIUrl":"10.1111/jdi.14293","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This analysis seeks to evaluate the cost-effectiveness of urine albumin-to-creatinine ratio testing compared with urine protein-creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A health-economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real-world Japanese data. Outcomes were considered over a lifetime horizon, and included costs, prevented dialyses, life years gained, quality-adjusted life years, and incremental cost-effectiveness ratios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Repeated urine albumin-to-creatinine ratio testing was found to be cost-effective compared with both urine protein-creatinine ratio testing and no urine testing, yielding incremental cost-effectiveness ratios of ¥2,652,693 and ¥2,460,453, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Repeated urine albumin-to-creatinine ratio testing is cost-effective compared with urine protein-creatinine ratio testing and no urine testing in Japanese individuals with type 2 diabetes, supporting existing clinical evidence that albumin-to-creatinine ratio testing should be used more widely, particularly compared with other urine tests such as urine protein-creatinine ratio testing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"108-119"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes","authors":"Yao-Hsien Tseng,&nbsp;Yu-Tse Tsan,&nbsp;Pau-Chung Chen","doi":"10.1111/jdi.14364","DOIUrl":"10.1111/jdi.14364","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Hyperglycemia was found to be associated with an increased risk of cancer in a general population cohort. However, it remains to be established whether the severity of diabetic complications is associated with cancer risk in patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We used the National Health Insurance Research Database from 2000 through 2013, including those with newly diagnosed diabetic patients (<i>n</i> = 616,742). We collected all vascular and metabolic complications to develop an adapted diabetic complication severity index (aDCSI), ranging from 0 to 13 annually, as proxies of the severity of diabetic complications and performed follow-up from the onset of diabetes until incident cancer, death, or the study end.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Within the mean follow-up period of 9 years, the rates of cancer incidence per 100,000 person-years were 815.2 vs 482.0 and 611.1 vs 358.9 for the top vs bottom quartiles, respectively, of aDCSI in men and women (adjusted HRs 1.17 (95% CI 1.10–1.25) and 1.20 (95% CI 1.10–1.30), respectively). The risk of cancer was 1.7- to 1.9-fold for the top vs bottom quartiles of aDCSI in diabetic onset age of 40–44 (HRs 1.74 (95% CI, 1.39–2.18) in men and HRs 1.93 (95% CI, 1.39–2.66) in women). However, among patients with diabetic onset age of 60–64, the associations between the severity of diabetic complications and cancer risk were attenuated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with higher severity of diabetic complications have an increased risk of cancer compared to those with the lowest severity, particularly for those with earlier onset and greater severity of diabetic complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"16-24"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based body composition analysis using computed tomography images predicts both prevalence and incidence of diabetes mellitus","authors":"Yoo Hyung Kim,&nbsp;Ji Won Yoon,&nbsp;Bon Hyang Lee,&nbsp;Jeong Hee Yoon,&nbsp;Hun Jee Choe,&nbsp;Tae Jung Oh,&nbsp;Jeong Min Lee,&nbsp;Young Min Cho","doi":"10.1111/jdi.14365","DOIUrl":"10.1111/jdi.14365","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim/Introduction</h3>\u0000 \u0000 <p>We assess the efficacy of artificial intelligence (AI)-based, fully automated, volumetric body composition metrics in predicting the risk of diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This was a cross-sectional and 10-year retrospective longitudinal study. The cross-sectional analysis included health check-up data of 15,330 subjects with abdominal computed tomography (CT) images between January 1, 2011, and September 30, 2012. Of these, 10,570 subjects with available follow-up data were included in the longitudinal analyses. The volume of each body segment included in the abdominal CT images was measured using AI-based image analysis software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Visceral fat (VF) proportion and VF/subcutaneous fat (SF) ratio increased with age, and both strongly predicted the presence and risk of developing diabetes. Optimal cut-offs for VF proportion were 24% for men and 16% for women, while VF/SF ratio values were 1.2 for men and 0.5 for women. The subjects with higher VF/SF ratio and VF proportion were associated with a greater risk of having diabetes (adjusted OR 2.0 [95% CI 1.7–2.4] in men; 2.9 [2.2–3.9] in women). In subjects with normal glucose tolerance, higher VF proportion and VF/SF ratio were associated with higher risk of developing prediabetes or diabetes (adjusted HR 1.3 [95% CI 1.1–1.4] in men; 1.4 [1.2–1.7] in women). These trends were consistently observed across each specified cut-off value.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>AI-based volumetric analysis of abdominal CT images can be useful in obtaining body composition data and predicting the risk of diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"272-284"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatokine leukocyte cell-derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction-associated steatotic liver disease in the general population","authors":"Keita Suzuki,&nbsp;Hiromasa Tsujiguchi,&nbsp;Akinori Hara,&nbsp;Yumie Takeshita,&nbsp;Hisanori Goto,&nbsp;Yujiro Nakano,&nbsp;Reina Yamamoto,&nbsp;Hiroaki Takayama,&nbsp;Atsushi Tajima,&nbsp;Tatsuya Yamashita,&nbsp;Masao Honda,&nbsp;Hiroyuki Nakamura,&nbsp;Toshinari Takamura","doi":"10.1111/jdi.14351","DOIUrl":"10.1111/jdi.14351","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Leukocyte cell-derived chemotaxin 2 (LECT2) is an obesity-associated hepatokine that causes skeletal muscle insulin resistance. Since LECT2 is up-regulated by the inactivation of the energy sensor AMPK in the liver, we hypothesized that LECT2 has potential as a biomarker for metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, we investigated whether circulating LECT2 levels are associated with insulin sensitivity, liver enzymes, and MASLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 138 Japanese individuals. Plasma LECT2 levels were measured using fasting blood samples. B-mode ultrasonography was used to assess hepatic steatosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age and body mass index (BMI) of participants were 63.5 ± 10.2 years and 23.0 ± 3.1 kg/m², respectively. Higher LECT2 levels positively correlated with homeostatic model assessment for insulin resistance (HOMA-IR) values and negatively correlated with the quantitative insulin sensitivity check index (QUICKI) among all participants (HOMA-IR; non-standardized <i>β</i> (<i>B</i>) = 6.38, <i>P</i> &lt; 0.01: QUICKI; <i>B</i> = −161, <i>P</i> &lt; 0.01). These correlations were stronger in the low BMI group (HOMA-IR; <i>B</i> = 13.85, <i>P</i> &lt; 0.01: QUICKI; <i>B</i> = −180, <i>P</i> &lt; 0.01). LECT2 levels also positively correlated with gamma-glutamyl transferase levels (<i>B</i> = 0.01, <i>P</i> = 0.01) and alanine aminotransferase levels (<i>B</i> = 0.33, <i>P</i> = 0.02). Higher LECT2 levels correlated with the prevalence of MASLD (odds ratio = 1.14, <i>P</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present results suggest the potential of plasma LECT2 levels as a biomarker for insulin resistance in individuals who are not overweight and the prevalence of MASLD in the general population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"298-308"},"PeriodicalIF":3.1,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis","authors":"Jie Gong,&nbsp;Fengwei Gao,&nbsp;Kangyi Jiang,&nbsp;Qingyun Xie,&nbsp;Xin Zhao,&nbsp;Zehua Lei","doi":"10.1111/jdi.14340","DOIUrl":"10.1111/jdi.14340","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the risk of biliary diseases in patients with type 2 diabetes mellitus (T2DM) or obesity treated with tirzepatide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Literature searches were performed using the PubMed, Web of Science, Cochrane Library, and CNKI databases until 20 May 2024. Randomized controlled studies (RCTs) investigating the safety of tirzepatide vs placebo/other hypoglycemic drugs in patients with T2DM or obesity were included. The safety outcomes mainly included the incidence of cholelithiasis, pancreatitis, cholecystitis, and gallbladder/biliary diseases. Cochrane Collaboration's tool for assessing the risk of bias was used to assess the quality of literature. Heterogeneity was evaluated using <i>I</i>² statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 12 high-quality RCTs (involving 12,351 patients) were included. The results of meta-analysis showed that tirzepatide was associated with gallbladder/biliary diseases (RR = 1.52; 95%CI: 1.17–1.98; <i>I</i>² = 0%, <i>P</i> = 0.76) and cholelithiasis (RR = 1.67; 95%CI: 1.14–2.44; <i>I</i>² = 0%, <i>P</i> = 0.95). Subgroup analysis based on the dose of tirzepatide found no dose–response relationship between different doses of tirzepatide and the risk of gallbladder/biliary diseases and cholelithiasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Based on the data currently available, tirzepatide is associated with the development of cholelithiasis in patients. However, the findings from RCTs still need to be further investigated in many post-marketing safety surveillance programs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"83-92"},"PeriodicalIF":3.1,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}